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Abstract
Background: Most pancreatoduodenectomy resections do not meet the minimum of 12 lymph nodes
recommended by the American Joint Committee on Cancer for accurate staging of periampullary malignancies.
The purpose of this study was to investigate factors affecting the likelihood of adequate nodal yield in
pancreatoduodenectomy specimens subject to routine pathological assessment.
Methods: Six hundred sixty-two patients subject to pancreatoduodenectomy between 1990 and 2013 for
pancreatic, ampullary, and common bile duct cancers were reviewed. Predictors of yielding at least 12 lymph nodes
were evaluated with a logistic regression model, and a survival analysis was carried out to verify the prognostic
implications of nodal counts.
Results: The median number of evaluated nodes was 17 (interquartile range 11 to 25), and less than 12 lymph nodes
were reported in surgical specimens of 179 (27 %) patients. Tumor diameter ≥20 mm (odds ratio [OR] 2.547, 95 %
confidence interval [CI] 1.225 to 5.329, P = 0.013), lymph node metastases (OR 2.642, 95 % CI 1.378 to 5.061, P = 0.004),
and radical lymphadenectomy (OR 5.566, 95 % CI 2.041 to 15.148, P = 0.01) were significant predictors of retrieving 12
or more lymph nodes. Lymph node counts did not influence the overall prognosis of the patients. However, a
subgroup analysis carried out for individual cancer sites demonstrated that removing at least 12 lymph nodes is
associated with better prognosis for pancreatic cancer.
Conclusions: Few variables affect adequate nodal yield in pancreatoduodenectomy specimens subject to routine
pathological assessment. Considering the ambiguities related to the only modifiable factor identified, appropriate
pathology training should be considered to increase nodal yield rather than more aggressive lymphatic dissection.
Keywords: Cancer of the ampulla of Vater, Cancer staging, Distal common bile duct cancer, Lymph nodes, Pancreatic
cancer
Background
Precise pathologic information is essential for clinical
decision-making in patients with solid tumors, including
those in the pancreaticoduodenal area (i.e., pancreatic,
common bile duct, and ampullary cancers). Therefore,
minimizing the risk of misclassification by harvesting an
adequate number of lymph nodes is important not only
for prognostic stratification but also for implementation
of adjuvant therapy when indicated.
The accuracy of staging lymph node status is directly pro-
portional to the number of lymph nodes retrieved and the
optimum cutoff value minimizing the stage migration
phenomenon reported previously for pancreatic cancer var-
ies from 10 to 15 [1, 2]. Moreover, many studies suggested
that removing at least ten lymph nodes is significantly asso-
ciated with improved survival regardless of the presence of
nodal metastases [1, 3, 4]. Others suggested that pathologic
assessment of more than 12 lymph nodes may provide
more accurate survival estimates for patients with node-
negative disease [5, 6]. Based on these observations, at least
12 lymph nodes are required for adequate staging for pan-
creatoduodenectomy specimens of pancreatic, distal bile
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duct, and ampullary cancer according to the most recent
edition of the American Joint Committee on Cancer
(AJCC) TNM classification [7]. Contrary to these recom-
mendations only about seven to eight nodes are dissected
in many institutions worldwide [2, 3, 8–10]. This carries
the risk of understaging, as an inadequate assessment of re-
gional lymph nodes may erroneously identify node-positive
patients as node negative.
Several previous reports demonstrated marked improve-
ments in lymph node counts by adopting adequate
methods of specimen processing by dedicated pathologists
[11–14]. Surprisingly, there are hardly any studies that dis-
cuss other factors affecting retrieval of the optimal 12
lymph nodes according to the current recommendations
of AJCC in patients undergoing pancreatoduodenectomy
for cancers of the periampullary area. As understaging
may have important therapeutic implications in routine
clinical practice, the aim of this study was to investigate
the impact of clinical and pathological factors on the like-
lihood of identifying the appropriate number of lymph
nodes for cancers of the pancreatic head, ampulla of Vater,
and common bile duct.
Methods
Patients
All patients undergoing pancreatic resections between
1990 and 2013 at our academic tertiary surgical center
were reviewed to identify pancreatoduodenectomies car-
ried out for malignancy of the pancreatic head, distal bile
duct, and ampulla of Vater. Patients operated for non-
malignant conditions were excluded. All data were pro-
spectively collected and recorded in a dedicated data-
base. Variables potentially affecting the number of
lymph nodes identified in surgical specimens were re-
trieved from the database and analyzed retrospectively,
including demographic data, pathologic features of the
tumor, and therapeutic interventions. Follow-up data
was collected based on clinical examinations performed
every 3–6 months after discharge and dates of death
from the census registry office. The study was approved
by the Bioethics Committee of Jagiellonian University.
Surgical procedures and pathological evaluation
All procedures were carried out by senior consultant
surgeons experienced in pancreato-biliary surgery and
using a similar technique of dissection. Primary tumors
were resected en bloc with pancreaticoduodenal lymph
nodes (groups 13 and 17 according to the Japanese Society
of Biliary Surgery (JSBS) [15] and Japan Pancreas Society
(JPS) [16]), whereas all other nodal stations were dissected
separately. The extent of lymphadenectomy was described
by the operating surgeon and classified as defined by the re-
cent guidelines [17, 18]. Briefly, standard lymphadenectomy
included resection of the following lymph node groups:
anterior and posterior pancreaticoduodenal (nos. 13 and
17), hepatoduodenal ligament (no. 12), nodes to the right
side of the superior mesenteric artery from its origin at the
aorta to the inferior pancreaticoduodenal artery (nos. 14a
and 14b), lymph nodes around the common hepatic artery
(no. 8a), and celiac trunk (no. 9), suprapyloric (no. 5), and
infrapyloric (no. 6) lymph nodes. Radical lymphadenectomy
included removal of lymph node groups described for
standard pancreatoduodenectomy along with para-aortic
lymph nodes (nos. 16a2 and 16b1) located between the
level of coeliac trunk and inferior mesenteric artery. The
choice of surgical technique and the extent of lymphade-
nectomy was made at the discretion of the operating sur-
geon without any preoperative allocation. Lymph nodes
were identified and retrieved from formalin-fixed surgical
specimens by the pathologists without any specific tech-
niques aimed at increasing nodal retrieval. In patients sub-
ject to total pancreatectomy, groups of lymph nodes
located around the pancreatic body and tail (i.e., nos. 10,
11, and 18) were not included in nodal counts for the pur-
pose of this study as they are not dissected at
pancreatoduodenectomy.
Statistical analysis
Mann-Whitney U and χ2 tests were used where appropri-
ate to identify the significant factors predictive of retriev-
ing at least 12 lymph nodes. Predictors significantly
associated with nodal count were used for the develop-
ment of a multivariate logistic regression model. The
probability for entering the model was 0.05 and for re-
moval from the model 0.100. Survival data was analyzed
according to the Kaplan-Meier method and included post-
operative mortality. The log-rank test was used to detect
differences between groups. All tests were two-sided and
P < 0.050 was considered statistically significant. Statistical
analysis was performed using the IBM® SPSS® Statistics
v.21 software package (IBM Corporation, NY).
Results
Study population
Among 842 pancreatoduodenectomies identified in our
database between 1990 and 2013, 662 were carried out for
pancreatic, ampullary, and common bile duct cancers. A
group of 180 patients were excluded due to the final
diagnosis of benign pancreatic disorders (n = 103) or other
malignancies (n = 77). Clinical and demographic data of
the selected population are summarized in Table 1.
Evaluation of lymph nodes
During the study period, 444 (67 %) resection specimens
were assessed onsite by one senior gastrointestinal path-
ologist (KN) and the remaining 218 (37 %) at a cooperat-
ing university pathology center. The median number of
evaluated nodes was 17 (interquartile range 11 to 25,
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range 2 to 92), and less than 12 lymph nodes were
reported in surgical specimens of 179 (27 %) patients.
Table 2 shows detailed pattern of lymph node distribu-
tion. The highest median nodal yield was found for the
pancreaticoduodenal lymph nodes (group nos. 13 and
17), followed by para-aortic (no. 16) and hepatoduodenal
ligament nodes (no. 12). Overall, positive lymph nodes
were identified in 396 (60 %) patients, including 264
patients with pancreatic cancer, 113 with ampullary
cancer, and 19 with common bile duct cancer. There
was no significant variability over time in the number of
identified lymph nodes (correlation coefficient r = 0.086,
P = 0.741) or the proportion of patients with 12 or more
nodes examined (r = 0.124, P = 0.660). Median node
counts were comparable among all operating surgeons
and were not associated with the type of the primary
tumor. There was a highly significant negative correl-
ation between patients’ body mass index (BMI) and the
proportion of patients with ≥12 lymph nodes examined
(correlation coefficient r = –0.679, P = 0.002), but no
such association was found for the absolute node count
(correlation coefficient r = –0.056, P = 0.349).
Predictive factors for lymph node yield
Table 3 shows results of a univariate analysis of factors
associated with removal of at least 12 lymph nodes.
Subsequent regression analysis, summarized in Table 4,
identified only three independent predictors for
adequate nodal yield, i.e., tumor diameter ≥20 mm (odds
ratio [OR] 2.547, 95 % confidence interval [CI] 1.225 to
5.329), lymph node metastases (OR 2.642, 95 % CI 1.378
to 5.061), and radical lymphadenectomy (OR 5.566, 95 %
CI 2.041 to 15.148).
Lymph node count and survival in patients with
malignancies
A group of 247 patients was alive after a median follow-up
of 94 months (range 24–295 months, final follow-up
December 2015). The overall median survival for patients
with pancreatic, ampullary, and common bile duct cancers
were 15 months (95 % CI 10.6–21.2), 52 months (95 %
CI 34.9–68.9), and 18 months (95 % CI 10.6–25.4). A
Table 2 Pattern of lymph node distribution (n = 662)
Group according
to JSBS/JPS
Location Median (IQR) of
examined nodes
No. (%) of patients with metastatic nodes by cancer site
Pancreatic
n = 388
Ampullary
n = 236
Bile duct
n = 38
5 Gastric lesser curve and suprapyloric 2 (1–3) 5 (1) 2 (1) 0
6 Gastric greater curve and infrapyloric 3 (1–5) 12 (2) 2 (1) 0
8 Common hepatic artery 2 (1–3) 49 (13) 6 (3) 0
9 Celiac trunk 2 (1–4) 24 (6) 4 (2) 0
12 Hepatoduodenal ligament 3 (2–5) 57 (15) 13 (6) 2 (5)
13 and 17 Pancreaticoduodenal 8 (6–12) 238 (61) 104 (44) 19 (50)
14 Superior mesenteric artery 2 (1–3) 44 (11) 6 (3) 2 (5)
16 Para-aortica 4 (2–6) 40 (10) 7 (4) 2 (5)
Overall All stations 17 (11–25) 264 (68) 113 (48) 19 (50)
Abbreviations: JSBS Japanese Society of Biliary Surgery, JPS Japan Pancreas Society, IQR interquartile range
aOnly patients with para-aortic lymph node dissection (n = 178)
Table 1 Baseline characteristics of the patients (n = 662)
Variable
Gender (F:M) 263:399
Age, median (IQR) years 60 (50–66)
Final diagnosis, n (%)
Pancreatic cancer 388 (59)
Cancer of the ampulla of Vater 236 (36)
Common bile duct cancer 38 (5)
Comorbidities, n (%)
Cardiocirculary 252 (38)
Pulmonary 33 (5)
Diabetes 132 (20)
Cirrhosis 7 (1)
ASA class, n (%)
I or II 470 (71)
III or IV 192 (29)
Preoperative biliary drainage, n (%)
None 364 (55)
Endoscopic 179 (27)
Operative 119 (18)
Body mass index, median (IQR) 24 (21–26)
Surgery, n (%)
Pancreatoduodenectomy (PD) 358 (54)
Pylorus-preserving PD 185 (28)
Total pancreatectomy 119 (18)
ASA American Society of Anesthesiologists, IQR interquartile range,
PD pancreatoduodenectomy
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subgroup analysis carried out for individual cancer sites
demonstrated that removing at least 12 lymph nodes is
associated with better 3- and 5-year survival rates
among patients with pancreatic cancer (Fig. 1). The sur-
vival benefit of higher nodal counts was maintained also
in patients subject to standard lymphadenectomy (Fig. 2).
No such effects were found for other malignancies. A
subgroup analysis was also carried out for the effects of
lymphadenectomy on patients’ survival, but the extent of
lymph node dissection (standard vs radical) did not influ-
ence prognosis or perioperative complications.
Discussion
Appropriate evaluation of lymph nodes in patients with
solid tumors has obvious implications for more accurate
staging. This study has demonstrated that the adequate
lymph node yield with standard pathologic processing of
pancreatoduodenectomy specimens in patients with
suspected periampullary malignancy is influenced by
only three factors, i.e., tumor diameter, metastases to
lymph nodes and extent of lymphadenectomy. Moreover,
evaluation of 12 or more nodes was associated with
survival benefit in patients with pancreatic cancer.
The amount of lymphatic tissue and numbers of lymph
nodes in the upper abdomen vary among individuals [19].
However, the yield of lymph nodes in all surgical speci-
mens, including pancreatoduodenectomy, is mostly influ-
enced by three main groups of variables, i.e., those related
to the patient and underlying pathology, to surgical inter-
vention, and to pathologic assessment of the specimen.
Although tissue processing and thoroughness of the
pathologic examination are the key factors for identifying
lymph nodes in surgical specimens, there is no general
agreement regarding the appropriate pathological evalu-
ation of pancreatoduodenectomy specimens, leading to
ambiguities in defining R1 resections and marked variabil-
ity in counts of lymph nodes identified in the peripancrea-
tic tissue [20, 21]. The average number of lymph nodes
identified in such specimens with standard techniques of
pathology sampling is five to seven [20]. Rarely, the num-
ber reaches 15 to 29 in some studies examining anatomic
distribution of peripancreatic lymph nodes or those apply-
ing meticulous processing of the specimen [12, 22, 23]. The
use of a standardized protocol for harvesting lymph nodes
in our department and the fact that almost 70 % of the
Table 3 Univariate analysis of factors associated with removal
of at least 12 lymph nodes
Factor Lymph node count Pb
<12 (n = 179) ≥12 (n = 483)
Gender 0.171
Female 79 (44) 184 (38)
Male 100 (56) 299 (62)
Age 0.125
<70 years 161 (90) 401 (83)
≥70 years 18 (10) 82 (17)
Cancer site 0.225
Pancreas 88 (49) 300 (62)
Ampulla of Vater 79 (44) 157 (33)
Common bile duct 12 (7) 26 (5)
Comorbidities 0.893
No 90 (50) 237 (49)
Yes 89 (50) 246 (51)
ASA class 0.259
I or II 134 (75) 336 (70)
III or IV 45 (25) 147 (30)
Preoperative biliary drainage 0.179
No 107 (60) 257 (53)
Yes 72 (40) 226 (47)
Body mass index 0.006
<25 91 (51) 314 (65)
≥25 88 (49) 169 (35)
Tumor diameter <0.001
<20 mm 66 (37) 101 (21)
≥20 mm 113 (63) 382 (79)
Lymph node metastases 0.001
No 111 (62) 155 (32)
Yes 68 (38) 328 (68)
Pathologist 0.767
Single 159 (89) 425 (88)
Various 20 (11) 58 (12)
Type of resectiona 0.001
Pancreatoduodenectomy (PD) 102 (57) 362 (75)
Pylorus-reserving PD 77 (43) 121 (25)
Lymphadenectomy 0.001
Standard 156 (87) 328 (68)
Radical 23 (13) 155 (32)
aIncluding total pancreatectomy with resection of the distal stomach (classified
as PD) and without (pylorus-preserving PD)
bChi-square test; numbers in parentheses are percentages
Table 4 Multivariate analysis of predictive factors for higher
lymph node counts (≥12)
Variable Odds
ratio
95 % confidence
interval
P
BMI (≥25) 0.831 0.431–1.612 0.582
Pylorus-preserving
resection (yes)
0.950 0.467–1.930 0.887
Diameter (≥20 mm) 2.547 1.225–5.329 0.013
Lymph node metastases (yes) 2.642 1.378–5.061 0.004
Lymphadenectomy (radical) 5.566 2.041–15.148 0.001
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specimens were examined by a single pathologist minimize
the risk that pathologist-related variability could bias results
of the current study and give the opportunity to evaluate
the influence of other factors on nodal yield.
There are very few studies reporting variables affecting
the number of lymph nodes dissected in pancreatic
surgery. Govindarajan et al. in a population of 2111 pa-
tients subject to pancreatoduodenectomy or total pancrea-
tectomy for pancreatic head cancer from 1998 through
2003 and identified from the Surveillance, Epidemiology
and End Results (SEER) registry found that younger age,
female sex, tumor diameter >2 cm, and node-positive sta-
tus increased the overall nodal count by 10 to 18 % [3].
Another analysis of the same database, but covering the
period from 1993 through 2003, demonstrated that the
likelihood of removing ten or more lymph nodes among
5465 pancreatoduodenectomies for periampullary carcin-
omas was higher in females, tumor diameter ≥2 cm,
pancreatic head cancers, and metastases to regional lymph
nodes [1]. However, the use of SEER data carries several
Fig. 1 Kaplan-Meier survival curves for pancreatic cancer according to the number of evaluated lymph nodes. Patients with 12 or more lymph
nodes removed had a significantly better long-term survival than those with 11 or fewer nodes (P = 0.036, log-rank test)
Fig. 2 Prognostic effects of lymph node counts in patients with pancreatic cancer subject to standard lymphadenectomy. Higher number of
resected lymph nodes (>12) was associated with improved survival (P = 0.029, log-rank test)
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disadvantages, including the unavailability of some vari-
ables potentially affecting lymph node counts such as BMI
or the extent of lymphadenectomy. Another important
issue that has not been addressed before is variability in
lymph node counts among different surgeons and pathol-
ogists. In contrast with both previous studies, our data-
base provides much more detailed information necessary
to better characterize potential predictors of nodal yield.
The association between the lymph node yield and node
positivity, as found in this study, is somewhat controver-
sial. Besides the SEER studies, two previous reports
suggested that in patients with pancreatic cancer subject
to various pancreatic resections there was a significant dif-
ference in the total lymph node count in cases with or
without nodal metastases of 19 vs 13 (P = 0.02) [5] and 15
vs 10 (P < 0.001) [24]. However, some other studies failed
to confirm such a relationship [6, 25–27]. These discrep-
ancies may derive from two potential aspects. First, the
presence of enlarged, metastatic nodes may force the
operating surgeon to a more extended dissection, and
second, metastatic lymph nodes are usually larger and
thus easier to identify by the pathologist. The proportion
of patients subject to radical lymphadenectomy in our
study was not influenced by the presence of metastatic
lymph nodes, but the overall median number of nodes
was significantly higher in this group (18 vs 15, P < 0.001).
As a subsequent analysis in individual nodal stations re-
vealed that the median count among subjects with meta-
static nodes was higher only for pancreaticoduodenal
stations (9 vs 7, P = 0.040), we may assume that lymph
node metastases did not affect the extent of surgery.
As reasonably expected, our study revealed that perform-
ing radical lymph node dissection, including para-aortic
nodes, is the most significant factor and the only surgeon-
dependent one to achieve the recommended nodal yield.
Although none of the prospective randomized clinical trials
on the extent of lymphadenectomy in periampullary malig-
nancies analyzed variables that potentially affect nodal yield,
median numbers of lymph nodes dissected in these studies
during standard pancreatoduodenectomy was 13 to 17 and
for extended 20 to 36 [23, 25, 28, 29]. The idea of radical
dissection is further supported by data accumulated over
recent years suggesting that the incidence of lymph node
metastasis to para-aortic nodal stations in periampullary
malignancies is relatively high and an appropriate degree of
lymphadenectomy is necessary to achieve an R0 resection
[30–35]. Although a recent meta-analysis of sixteen studies
comprising 1909 patients comparing outcomes of standard
and extended pancreatoduodenectomy showed similar peri-
operative morbidity and mortality rates, it also emphasized
no improved survival after the latter procedure (hazard
ratio 0.77, P = 0.100) [36]. Therefore, the only benefit of the
latter procedure seems to be associated with more accurate
staging of nodal disease even if some controversies still
exist about station 16b1 considered as one of the major
lymphatic drainage routes for pancreatic head cancer [18].
Removal of the recommended number of lymph nodes
was not associated with any clear survival benefit in the
whole population of patients with periampullary malig-
nancies. However, if the tumors were analyzed separately,
pancreatic cancer demonstrated better survival among
patients with ≥12 lymph nodes resected regardless the
extent of lymphadenectomy. This is similar to some
observations using cutoff values of 10 or 12 lymph nodes;
however, the relationship between node counts and
survival is not clear as previous studies on periampullary
malignancies reported conflicting results [1, 3–6, 37].
The limitations of the present study are related to its
retrospective design and potential bias resulting from such
analyzes. In particular, we were unable to account for the
premises for performing a more extensive lymph node
dissection, such as finding suspicious nodes intraopera-
tively or decisions made a priori, even though data analysis
showed no such correlation. Nevertheless, the lack of
major changes observed over time in the absolute number
of lymph nodes harvested and the proportion of patients
with ≥12 nodes support the assumption that the surgical
technique remained unchanged over the study period.
Conclusions
In conclusion, this study demonstrated that only few factors
were associated with the likelihood of removing at least 12
lymph nodes in surgical specimens of patients subject to
pancreatoduodenectomy for suspected periampullary
malignancy, i.e., tumor diameter, lymph node metastases,
and radical lymphadenectomy. However, the latter and the
only modifiable factor offered no clear survival benefit in
previous randomized clinical trials and potentially may
increase postoperative morbidity. Therefore, appropriate
pathology training should be considered to increase nodal
yield rather than more aggressive lymphatic dissection.
Abbreviations
AJCC: American Joint Committee on Cancer; ASA: American Society of
Anesthesiologists; BMI: Body mass index; CI: Confidence interval;
IQR: Interquartile range; JPS: Japan Pancreas Society; JSBS: Japanese Society
of Biliary Surgery; OR: Odds ratio; PD: Pancreatoduodenectomy;
SEER: Surveillance, Epidemiology, and End Results; TNM: Tumor, lymph
nodes, distant metastases
Acknowledgements
Not applicable.
Funding
This study was financially supported by the Polish National Science Centre,
grant no. N N403 084939 and the Leading National Research Centre (KNOW)
of the Medical Faculty, Jagiellonian University Medical College. The provider
of the financial support was not involved in the study design, collection,
analysis, and interpretation of the data; in the writing of the manuscript; and
in the decision to submit the manuscript for publication.
Sierzega et al. World Journal of Surgical Oncology  (2016) 14:248 Page 6 of 8
Availability of data and materials
The manuscript does not refer to any new software, application, or tool.
The authors do not wish to share data analyzed in this manuscript as no
such consent was provided by the patients treated and no approval of the
Bioethics Committee was obtained.
Authors’ contributions
MS, AM, and JK were responsible for the conception of the work. MS and ŁB
helped in the data collection. MS contributed to the data analysis and
interpretation. MS helped in drafting the article. AM and JK did the critical
revision of the article. MS, ŁB, AM, and JK gave final approval of the version
to be published.
Competing interests
The authors declare that they have no competing interest.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All the patients gave informed consent for collection and processing of
clinical and pathology related data throughout the period covered by this
study. The study was approved by the Bioethics Committee of Jagiellonian
University for a retrospective analysis of the collected data.
Received: 14 June 2016 Accepted: 13 September 2016
References
1. Gutierrez JC, Franceschi D, Koniaris LG. How many lymph nodes properly
stage a periampullary malignancy? J Gastrointest Surg. 2008;12(1):77–85.
2. Tomlinson JS, Jain S, Bentrem DJ, Sekeris EG, Maggard MA, Hines OJ, Reber
HA, Ko CY. Accuracy of staging node-negative pancreas cancer: a potential
quality measure. Arch Surg. 2007;142(8):767–23.
3. Govindarajan A, Tan JC, Baxter NN, Coburn NG, Law CH. Variations in
surgical treatment and outcomes of patients with pancreatic cancer: a
population-based study. Ann Surg Oncol. 2008;15(1):175–85.
4. Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic
cancer survival: information from a large US population database. Ann Surg
Oncol. 2006;13(9):1189–200.
5. House MG, Gonen M, Jarnagin WR, D’Angelica M, DeMatteo RP, Fong Y,
Brennan MF, Allen PJ. Prognostic significance of pathologic nodal status in
patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11(11):
1549–55.
6. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD,
Wolfgang C, Hruban RH, Schulick RD, Yeo CJ, Choti MA. Prognostic
relevance of lymph node ratio following pancreaticoduodenectomy for
pancreatic cancer. Surgery. 2007;141(5):610–8.
7. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer
staging manual (7th edn). New York: Springer; 2010.
8. Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD,
Choti MA, Pawlik TM. Impact of total lymph node count and lymph node
ratio on staging and survival after pancreatectomy for pancreatic
adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;
15(1):165–74.
9. Westgaard A, Laronningen S, Mellem C, Eide TJ, Clausen OP, Moller B,
Gladhaug IP. Are survival predictions reliable? Hospital volume versus
standardisation of histopathologic reporting for accuracy of survival
estimates after pancreatoduodenectomy for adenocarcinoma. Eur J Cancer.
2009;45(16):2850–9.
10. Bilimoria KY, Talamonti MS, Wayne JD, Tomlinson JS, Stewart AK, Winchester
DP, Ko CY, Bentrem DJ. Effect of hospital type and volume on lymph node
evaluation for gastric and pancreatic cancer. Arch Surg. 2008;143(7):671–8.
11. Jeyarajah DR, Khithani A, Siripurapu V, Liu E, Thomas A, Saad AJ. Lymph
node retrieval in pancreaticoduodenectomy specimens: does educating the
pathologist matter? HPB (Oxford). 2014;16(3):263–6.
12. Liszka L, Pajak J, Zielinska-Pajak E, Golka D, Mrowiec S, Lampe P. Different
approaches to assessment of lymph nodes and surgical margin status in
patients with ductal adenocarcinoma of the pancreas treated with
pancreaticoduodenectomy. Pathology. 2010;42(2):138–46.
13. Rowsell CH, Hanna S, Hsieh E, Law C, Khalifa MA. Improved lymph node
retrieval in Whipple specimens as a result of implementation of a new
uncinate margin protocol. HPB (Oxford). 2007;9(5):388–91.
14. Staley CA, Cleary KR, Abbruzzese JL, Lee JE, Ames FC, Fenoglio CJ, Evans DB.
The need for standardized pathologic staging of pancreaticoduodenectomy
specimens. Pancreas. 1996;12(4):373–80.
15. Japanese Society of Biliary Surgery. Classification of biliary tract carcinoma
(Second English edn). Tokyo: Kanehara & Co., Ltd; 2004.
16. Japanese Pancreas Society. Classification of pancreatic carcinoma (Second
English edn). Tokyo: Kanehara & Co., Ltd; 2003.
17. Pedrazzoli S, Beger HG, Obertop H, Andren-Sandberg A, Fernandez-Cruz L,
Henne-Bruns D, Luttges J, Neoptolemos JP. A surgical and pathological
based classification of resective treatment of pancreatic cancer. Summary of
an international workshop on surgical procedures in pancreatic cancer. Dig
Surg. 1999;16(4):337–45.
18. Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andren-
Sandberg A, Asbun HJ, Bockhorn M, Buchler MW, Conlon KC, Fernandez-
Cruz L, Fingerhut A, Friess H, Hartwig W, Izbicki JR, Lillemoe KD, Milicevic
MN, Neoptolemos JP, Shrikhande SV, Vollmer CM, Yeo CJ, Charnley RM,
International Study Group on Pancreatic S. Definition of a standard
lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a
consensus statement by the International Study Group on Pancreatic
Surgery (ISGPS). Surgery. 2014;156(3):591–600.
19. Wagner PK, Ramaswamy A, Ruschoff J, Schmitz-Moormann P, Rothmund M.
Lymph node counts in the upper abdomen: anatomical basis for
lymphadenectomy in gastric cancer. Br J Surg. 1991;78(7):825–7.
20. Adsay NV, Basturk O, Altinel D, Khanani F, Coban I, Weaver DW, Kooby DA,
Sarmiento JM, Staley C. The number of lymph nodes identified in a simple
pancreatoduodenectomy specimen: comparison of conventional vs orange-
peeling approach in pathologic assessment. Mod Pathol. 2009;22(1):107–12.
21. Verbeke CS. Resection margins and R1 rates in pancreatic cancer—are we
there yet? Histopathology. 2008;52(7):787–96.
22. Cubilla AL, Fortner J, Fitzgerald PJ. Lymph node involvement in carcinoma
of the head of the pancreas area. Cancer. 1978;41(3):880–7.
23. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK,
Coleman J, Abrams RA, Hruban RH. Pancreaticoduodenectomy with or
without distal gastrectomy and extended retroperitoneal lymphadenectomy
for periampullary adenocarcinoma, part 2: randomized controlled trial
evaluating survival, morbidity, and mortality. Ann Surg. 2002;236(3):355–66.
24. Konstantinidis IT, Deshpande V, Zheng H, Wargo JA, Fernandez-del
Castillo C, Thayer SP, Androutsopoulos V, Lauwers GY, Warshaw AL,
Ferrone CR. Does the mechanism of lymph node invasion affect
survival in patients with pancreatic ductal adenocarcinoma? J
Gastrointest Surg. 2010;14(2):261–7.
25. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N,
Sargent DJ. A prospective randomized trial comparing standard
pancreatoduodenectomy with pancreatoduodenectomy with extended
lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery.
2005;138(4):618–28.
26. Massucco P, Ribero D, Sgotto E, Mellano A, Muratore A, Capussotti L.
Prognostic significance of lymph node metastases in pancreatic head
cancer treated with extended lymphadenectomy: not just a matter of
numbers. Ann Surg Oncol. 2009;16(12):3323–32.
27. Malleo G, Maggino L, Capelli P, Gulino F, Segattini S, Scarpa A, Bassi C,
Butturini G, Salvia R. Reappraisal of nodal staging and study of lymph node
station involvement in pancreaticoduodenectomy with the standard
international study group of pancreatic surgery definition of
lymphadenectomy for cancer. J Am Coll Surg. 2015;221(2):367–79.
28. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel
G, Dhaene K, Michelassi F. Standard versus extended lymphadenectomy
associated with pancreatoduodenectomy in the surgical treatment of
adenocarcinoma of the head of the pancreas: a multicenter, prospective,
randomized study. Lymphadenectomy Study Group. Ann Surg.
1998;228(4):508–17.
29. Nimura Y, Nagino M, Kato H, Miyagawa S, Yamaguchi A, Kinoshita T.
Regional versus extended lymph node dissection in radical
pancreaticoduodenectomy for pancreatic cancer: a multicenter, randomized
controlled trial. HPB. 2004;6 Suppl 1:2.
30. Kanda M, Fujii T, Nagai S, Kodera Y, Kanzaki A, Sahin TT, Hayashi M, Yamada
S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A. Pattern of lymph
node metastasis spread in pancreatic cancer. Pancreas. 2011;40(6):951–5.
Sierzega et al. World Journal of Surgical Oncology  (2016) 14:248 Page 7 of 8
31. Kayahara M, Nagakawa T, Kobayashi H, Mori K, Nakano T, Kadoya N, Ohta T,
Ueno K, Miyazaki I. Lymphatic flow in carcinoma of the head of the
pancreas. Cancer. 1992;70(8):2061–6.
32. Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Ueno K, Tajima H, Elnemr A,
Miwa K. Analysis of paraaortic lymph node involvement in pancreatic
carcinoma: a significant indication for surgery? Cancer. 1999;85(3):583–90.
33. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T,
Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K.
Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004;
28(3):219–30.
34. Nagakawa T, Kobayashi H, Ueno K, Ohta T, Kayahara M, Miyazaki I. Clinical
study of lymphatic flow to the paraaortic lymph nodes in carcinoma of the
head of the pancreas. Cancer. 1994;73(4):1155–62.
35. Nakao A, Harada A, Nonami T, Kaneko T, Murakami H, Inoue S, Takeuchi Y,
Takagi H. Lymph node metastases in carcinoma of the head of the
pancreas region. Br J Surg. 1995;82(3):399–402.
36. Iqbal N, Lovegrove RE, Tilney HS, Abraham AT, Bhattacharya S, Tekkis PP,
Kocher HM. A comparison of pancreaticoduodenectomy with extended
pancreaticoduodenectomy: a meta-analysis of 1909 patients. Eur J Surg
Oncol. 2009;35(1):79–86.
37. Falconi M, Crippa S, Dominguez I, Barugola G, Capelli P, Marcucci S, Beghelli
S, Scarpa A, Bassi C, Pederzoli P. Prognostic relevance of lymph node ratio
and number of resected nodes after curative resection of ampulla of Vater
carcinoma. Ann Surg Oncol. 2008;15(11):3178–86.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Sierzega et al. World Journal of Surgical Oncology  (2016) 14:248 Page 8 of 8
